Q1 25 EPS
$-0.05
MISS 225.00%
Est. $0.04
Q1 25 Revenue
$777.9M
BEAT +1.71%
Est. $764.8M
vs S&P Since Q1 25
-22.0%
TRAILING MARKET
AHCO +9.2% vs S&P +31.3%
Market Reaction
Did AHCO Beat Earnings? Q1 2025 Results
AdaptHealth delivered a split verdict in Q1 2025, posting revenue of $777.88 million that edged past the $764.77 million consensus by 1.71% and surged 30.9% year-over-year, yet stumbled badly on the bottom line, reporting an EPS of -$0.05 against an … Read more AdaptHealth delivered a split verdict in Q1 2025, posting revenue of $777.88 million that edged past the $764.77 million consensus by 1.71% and surged 30.9% year-over-year, yet stumbled badly on the bottom line, reporting an EPS of -$0.05 against an expected $0.04, a miss of 225.00%. The earnings shortfall was rooted in meaningful profitability compression, with Adjusted EBITDA falling 19.3% to $127.94 million and margins contracting to 16.4% from 20.0% a year earlier, as higher costs of net revenue weighed heavily on operating income. A bright spot was cash flow from operations, which nearly doubled to $95.53 million, reflecting tighter working capital management. Strategically, AdaptHealth continued reshaping its portfolio through asset divestitures in its Wellness at Home segment, which prompted a modest trim to full-year guidance, with net revenue now expected between $3.18 billion and $3.32 billion and Adjusted EBITDA between $665 million and $705 million, while free cash flow guidance of $180 million to $220 million held firm. Reports of a new DME acquisition suggest the company is quietly balancing dispositions with selective growth moves.
Key Takeaways
- • Diabetes Health segment showed signs of improvement for second consecutive quarter
- • Operating cash flow nearly doubled year-over-year to $95.5 million
- • Cost of net revenue increased to $657.4 million from $635.0 million, pressuring margins
- • Adjusted EBITDA margin contracted to 16.4% from 20.0%
AHCO YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
“Amid elevated uncertainty in the external environment, we at AdaptHealth have stayed the course, with a relentless focus on improving our business and providing exceptional service to the 4.2 million patients that depend on us.”
— Suzanne Foster, Q1 2025 Earnings Press Release
AHCO Earnings Trends
AHCO vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
AHCO EPS Trend
Earnings per share: estimate vs actual
AHCO Revenue Trend
Quarterly revenue: estimate vs actual
AHCO Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 | — | — | — | — | — |
| Q1 26 MISS | $0.01 | $-0.12 | -1,125.64% | $819.8M | +2.91% |
| Q4 25 MISS FY | $0.34 | $-0.76 | -323.86% | $846.3M | +1.77% |
| FY Full Year | $0.71 | $-0.52 | -172.93% | $3.24B | +0.45% |
| Q3 25 MISS | $0.24 | $0.16 | -33.14% | $820.3M | +2.63% |
| Q2 25 MISS | $0.16 | $0.10 | -36.79% | $800.4M | -0.43% |
| Q1 25 MISS | $0.04 | $-0.05 | -225.00% | $777.9M | +1.71% |